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the most important component of treatment for these 
patients, it confers a modest survival advantage. 
Recently, increased knowledge of the key molecular 
signaling pathways involved in gastric carcinogenesis 
has led to the discovery of specific molecular-targeted 
therapeutic agents. Some of these agents such as trastu-
zumab and ramucirumab have changed the treatment 
paradigm for this disease. In this paper, we will sum-
marize the current clinical status of targeted drug 
therapy in the management of GC. 
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Core tip: Systemic chemotherapy confers a modest 
survival advantage in patients with advanced gastric 
cancer. The new therapeutic agents that target various 
inter- and intracellular signaling transduction pathways 
offer the promise of improved clinical outcomes in 
selected patients. The success of some of these agents 
has changed the treatment paradigm for advanced 
gastric cancer. We herein discuss the current and 
potential future roles of targeted therapy in the manage-
ment of this malignancy.
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INTRODUCTION
Gastric cancer (GC) is a very aggressive tumor and 
is currently the third leading cause of cancer-related 
deaths in both sexes at the world level (8.8% of the 
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Abstract
In the West in particular, the vast majority of gastric 
cancer (GC) patients present with advanced-stage 
disease. Although combination chemotherapy is still 
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total)[1,2]. At initial diagnosis, a significant proportion of 
Western GC patients (65%) are found to have unresec­
table disease or distant metastases. In Japan and 
South Korea, where nationwide government­sponsored 
screening programs have been established, still up to 
80% of patients who undergo a curative resection for 
GC develop locoregional or distant recurrence[2,3]. 
The clinical management of patients with advanced 
GC remains one of the most challenging tasks in clinical 
oncology. Until recently, systemic chemotherapy alone 
has been the mainstay of treatment for these patients[4]. 
However, the disease often exhibits relative resistance to 
chemotherapeutic agents, and a satisfactory response 
is achieved only in a minority of the patients[5,6]. In addi-
tion, although systemic chemotherapy can substantially 
increase symptom control and improve the patient’s 
quality of life, its long-term results are still not satisfac-
tory and unfortunately many patients die less than a 
year after starting therapy[5,6]. 
Thus, there is undoubtedly a need to develop more 
effective treatment strategies for this formidable disease. 
As in other solid tumors, the uses of targeted agents 
that block vital inter­ and intracellular signaling path­
ways have recently emerged as a strategy for the 
treatment of advanced GC[7-12]. Significant advances in 
our understanding of the underlying biologic processes 
of GC have recently expanded the number and range of 
potential therapeutic targets. Targeted agents may be 
used either alone or in combination with anti­neoplastic 
agents for patients with both chemotherapy­naïve and 
chemotherapy­refractory disease. Some of these, such 
as trastuzumab and ramucirumab have been shown to 
have significant therapeutic activity and a good safety 
profile, have changed the treatment paradigm, and are 
therefore currently licensed in the United States and 
Europe as part of the management of patients with GC. 
In this review, we will outline well-established tar-
geted treatments for GC and discuss novel agents 
currently in development as well as some directions for 
future research. 
Anti-epidermal growth factor receptor therapies
The epidermal growth factor receptor (EGFR) belongs to 
the ErbB family of receptor tyrosine kinases (RTK), which 
contains four closely related members: ErbB1 (HER1 
or EGFR), ErbB2 (Her2/neu), ErbB3 and ErbB4[13,14]. 
EGFR activation by one of its ligands initiates diverse 
downstream signaling pathways including the RAS/RAF/
MAP kinase and PI3K/Akt/mTOR signaling networks. 
Both pathways play a vital role in several critical cellular 
processes including proliferation, growth, survival, 
motility, and tissue invasion[13,14]. 
EGFR overexpression has been correlated with 
more aggressive tumor behavior and a worse clinical 
results in patients with GC, suggesting that EGFR is 
therapeutic target for this aggressive malignancy[13,14]. 
The current therapeutic strategies targeting EGFR 
include neutralizing monoclonal antibodies (moAbs) 
directed against the extracellular receptor domain and 
small molecule tyrosine kinase inhibitors (TKIs) of the 
intracellular tyrosine kinase domain (Figure 1).
Cetuximab and panitumumab are engineered anti­
bodies that bind to EGFR with higher affinity compared 
to its natural ligands[15,16]. Several phase II clinical 
trials have tested the feasibility of adding cetuximab 
to different chemotherapy regimens including 5­FU/
folinic acid (LV)/irinotecan, 5­FU/LV/oxaliplatin 
(FOLFOX), docetaxel/cisplatin, capecitabine/cisplatin, 
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Figure 1  Molecular targets and relevant drugs in metastatic gastric cancer. HER: Human epidermal growth factor receptor; VEGF: Vascular endothelial growth 
factor; VEGFR: Vascular endothelial growth factor receptor; PDGFR: Platelet-derived growth factor receptor; HGF: Hepatocyte growth factor; FGFR2: Fibroblast 
growth factor receptor 2; IGF-1: Insulin-like growth factor 1; Raf: GTPase Raf; Ras: GTPase Ras; MEK: MAP kinase; ERK: Extracellular-signal-regulated kinase; PI3K: 
Phosphatidylinositol 3-kinase; PTEN: Phosphatase and tensin homolog; AKT: Protein kinase B; mTOR: Mammalian target of rapamycin. 
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and capecitabine/oxaliplatin for chemotherapy­naïve 
advanced GC patients[17-20]. In these trials, overall 
response rates ranged from 41% to 69%, median 
progression­free survival (PFS) varied from 5 to 8.5 mo, 
and median overall survival (OS) varied from 9 to 16.6 mo. 
A randomized phase II clinical study (CALGB 80403/
ECOG 1206) evaluated three different conventional 
chemotherapy regimens (Epirubicin, cisplatin and 5­FU 
vs irinotecan and cisplatin vs FOLFOX) in combination 
with cetuximab. Response rates were 58%, 38%, and 
51%, respectively, and median OS was 8.6 and 10 mo, 
respectively. Cetuximab combined with FOLFOX was 
found to be the least toxic of the three[21]. 
Unfortunately, these promising initial outcomes 
were not verified in the phase III EXPAND trial[22]. In 
this study, 904 previously untreated metastatic GC and 
gastro­esophageal junction (GEJ) cancer patients were 
randomly allocated to receive chemotherapy (cisplatin 
and capecitabine) with or without cetuximab[22]. No 
differences in clinical outcome were found between 
treatment groups, and the primary and secondary 
efficacy endpoints were not met; the median PFS and 
OS were 4.4 mo (95%CI: 4.2 to 5.5 mo) and 9.4 mo 
(95%CI: 8.3 to 10.6 mo), respectively in the combined 
therapy group compared with 5.6 mo (95%CI: 5.1 
to 5.7 mo) and 10.7 mo (95%CI: 9.4 to 11.3 mo), 
respectively in the chemotherapy­alone group (P = 
0.32 and P = 0.95 for PFS and OS, respectively). The 
addition of cetuximab also did not increase the overall 
response rate, which was 30% and 29% with or without 
cetuximab, respectively (Table 1). 
Similarly, the phase III REAL­3 trial was performed 
to determine the effects of adding panitumumab to 
a combination chemotherapy regimen of epirubicin, 
oxaliplatin, and capecitabine (EOX) in patients with 
advanced esophago­gastric adenocarcinoma[23]. In this 
trial, patients were randomly allocated to receive EOX 
or a modified EOX plus panitumumab. Disappointingly, 
adding panitumumab to EOX chemotherapy resulted 
in worsened OS [8.8 mo compared with 11.3 mo 
for the EOX regimen (HR = 1.37; P = 0.013)]. A 
trend toward a shorter PFS was also seen in patients 
receiving panitumumab (6.0 mo vs 7.4 mo, HR = 1.22; 
P = 0.068). The panitumumab­containing arm was 
associated with an increased rate of grade 3-4 diarrhea 
(17% vs 11%), rash (11% vs 1%), mucositis (5% 
vs none), and hypomagnesaemia (5% vs none) but 
reduced rate of neutropenia (13% vs 28%). 
Lastly, other novel humanized IgG1 anti­EGFR moAbs 
including matuzumab and nimotuzumab have also 
been investigated as first- or second-line treatment 
for advanced GC, and have also failed to generate a 
strong efficacy signal[24­26]. The small molecule EGFR 
TKIs have not been extensively studied in the treatment 
of advanced GC largely due to their limited activity in 
this setting[27,28]. Why EGFR­targeting strategies have 
failed to be successful in this disease in spite of lack of 
activating KRAS mutations and in spite of good biologic 
rationale remains a mystery. 
Anti-HER2 (ERBB2) therapy
As previously mentioned HER2 is another member 
of the ERB family of receptor tyrosine kinases[29]. 
Overexpression and amplification of the HER2 is 
detected in 10%­38% of GC patients[30]. Although 
the association between HER2 status and prognosis 
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  Author/trial Line of
treatment 
Target Agent Treatment ORR (%) PFS (mo) OS (mo)
  Lordick et al[22] (2013)/ 
  EXPAND
First EGFR Cetuximab Cisplatin/capecitabine
± cetuximab
30 vs 29
P = 0.77
4.4 vs 5.6
P = 0.32
9.4 vs 10.7
P = 0.95
  Waddell et al[23] (2013)/REAL-3 First EGFR Panitumumab EOX ± panitumumab 46 vs 42
P = 0.42
6.0 vs 7.4
P = 0.068
8.8 vs 11.3
P = 0.013
  Bang et al[32] (2010)/
  ToGA
First HER2 Trastuzumab Cisplatin/capecitabine 
or 5-FU ± trastuzumab
47 vs 35
P = 0.0017
6.7 vs 5.5
P = 0.0002
13.8 vs 11.1
P = 0.0046
  Hecht et al[34] (2013)/
  LoGIC
First EGFR/
HER2
Lapatinib CAPOX ± lapatinib 53 vs 40
P = NA
6.0 vs 5.4
P = 0.1
12.2 vs 10.5
P = 0.35
  Ohtsu et al[37] (2011)/
  AVAGAST
First VEGF-A Bevacizumab Cisplatin/capecitabine
± bevacizumab
46 vs 37.4
P = 0.03
6.7 vs 5.3
P = 0.037
12.1 vs 10.1
P = 0.1002
  Shen et al[39] (2015)/
  AVATAR
First VEGF-A Bevacizumab Cisplatin/capecitabine
± bevacizumab
40.7 vs 33.7
P = 0.348
6.3 vs 6.0
P = 0.47
11.4 vs 10.5
P = 0.55
  Bang et al[35] (2014)/TyTAN Second EGFR/
HER2
Lapatinib Paclitaxel ± lapatinib 27 vs 9
P < 0.001
5.4 vs 4.4
P = 0.13
11.0 vs 8.9
P = 0.1044
  Fuchs et al[41] (2014)/
  REGARD
Second VEGFR-2 Ramucirumab BSC + ramucirumab
or placebo
3.4 vs 2.6
P = 0.76
2.1 vs 1.3
P < 0.0001
5.2 vs 3.8
P = 0.0473
  Wilke et al[43] (2014)/
  RAINBOW 
Second VEGFR-2 Ramucirumab Paclitaxel + 
ramucirumab or placebo
28 vs 16
P = 0.0001
4.4 vs 2.9
P < 0.0001
9.6 vs 7.4
P = 0.017
  Ohtsu et al[52] (2013)/
  GRANITE-1
Second or 
third
mTOR Everolimus Everolimus or placebo 4.5 vs 2.1
P = NA
1.7 vs 1.4
P < 0.001
5.4 vs 4.3
P = 0.124
Table 1  Summary of completed phase III trials of targeted agents in the treatment of advanced gastric and gastroesophageal 
adenocarcinoma
ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; EGFR: Epidermal growth factor receptor; EOX: Epirubicin, oxaliplatin and 
capecitabine; HER2: Human epidermal growth factor receptor 2; 5-FU: 5-fluorouracil; CAPOX: Capecitabine and oxaliplatin; NA: Not available; VEGF-A: 
Vascular endothelial growth factor A; VEGFR-2: Vascular endothelial growth factor receptor 2; mTOR: Mammalian target of rapamycin.
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chemotherapy. 
Lapatinib is an oral small­molecule tyrosine kinase 
inhibitor of EGFR and HER2 that blocks their tyrosine 
kinase activities. Two phase III trials were performed 
to explore the effectiveness of lapatinib in first­ and 
second-line treatment of advanced GC. The LoGIC 
III trial investigated the efficacy of lapatinib when 
administered in combination with capecitabine plus 
oxaliplatin (CAPOX) as first­line therapy[34]. In total, 
545 patients whose tumors overexpressed HER­2 were 
assigned to receive CAPOX plus lapatinib or placebo. 
No significant difference in survival between the two 
treatment arms was detected. Median OS and PFS in 
the chemotherapy + lapatinib group were 12.2 and 
6 mo, respectively, compared to 10.5 and 5.4 mo in 
the control group. Similarly, in the phase III TyTan trial 
conducted in Asia, 430 patients with advanced GC who 
had experienced failure of fluoropyrimidine and cisplatin­
based chemotherapy and exhibited FISH­confirmed 
HER2 amplification received lapatinib plus weekly 
paclitaxel or weekly paclitaxel alone[35]. Although, the 
addition of lapatinib to paclitaxel extended the primary 
endpoint of OS from a median of 8.9 mo to 11.0 mo, 
this improvement failed to reach statistical significance 
(P = 0.1044). The further subgroup analysis revealed a 
statistically significant benefit in both OS and PFS from 
the addition of lapatinib to chemotherapy in patients 
with HER2 IHC3+ tumors and in Chinese patients. 
Targeting angiogenesis pathways
Angiogenesis is necessary for tumors to grow beyond 
a certain size, survive or spread. Vascular endothelial 
growth factor (VEGF) and its receptors (VEGFR1, 
VEGFR2 and VEGFR3) are important players in the 
development of this process. Binding of the ligand 
VEGF­A to VEGFR­2 triggers a signaling cascade leading 
to endothelial cell proliferation, migration, new vessel 
formation, and sustained angiogenesis[24]. Therefore, 
inhibition of the VEGF signaling has become a useful 
clinical maneuver in the treatment of several types of 
cancer. 
Anti-VEGF moAb: Bevacizumab is a fully human moAb 
targeting VEGF­A[36]. The potential role of this drug in 
the management of patients with metastatic GC was 
evaluated in the phase III AVAGAST and AVATAR trials. 
The AVAGAST trial was global, randomized, placebo­
controlled trial conducted for evaluation of the benefits of 
bevacizumab when added to first­line capecitabine and 
cisplatin chemotherapy in 774 metastatic GC patients[37]. 
The trial did not show any significant improvement in 
OS in the bevacizumab cohort. Median OS was 12.1 mo 
with bevacizumab plus chemotherapy and 10.1 mo with 
placebo plus chemotherapy (HR = 0.87; 95%CI: 0.73 to 
1.03; P = 0.1002). Despite this, both median PFS (6.7 
mo vs 5.3 mo; HR = 0.80; 95%CI: 0.68 to 0.93; P = 
0.0037) and overall response rate (46.0% vs 37.4%; P 
= 0.0315) were significantly increased by the addition of 
bevacizumab vs placebo. Preplanned subgroup analysis 
in GC still controversial, the results of some clinical 
studies have suggested that patients with HER2 
negative disease have a more favorable prognosis 
than those with HER2 positive disease[29,31]. Perhaps 
one of the most convincing data supporting the clinical 
benefits of targeted therapy in advanced GC come 
from the phase III ToGA study[32]. This landmark study 
investigated the addition of trastuzumab, a moAb 
that binds to the extracellular ligand binding domain 
of the HER2 receptor, to combination chemotherapy 
(cisplatin and either capecitabine or 5­FU) in patients 
with previously untreated HER2 overexpressing [defined 
as HER2 fluorescence in situ hybridization (FISH) 
positive or immunohistochemistry (IHC) 3 positive], 
and advanced gastric or GEJ cancer. Over 3000 patients 
were screened for the study. Among the 594 enrolled 
patients, 296 received chemotherapy alone and 298 
received chemotherapy plus trastuzumab. Patients 
receiving the combined therapy achieved improvement 
in all measures of efficacy including OS (13.8 mo vs 
11.1 mo; HR = 0.74, P = 0.0046), PFS (6.7 mo vs 5.5 
mo; HR = 0.71, P = 0.0002), and overall response 
rate (47% vs 35%, P = 0.0017). A post hoc subgroup 
analysis of the study demonstrated that the patients 
with strongly HER­2 positive tumors (defined as IHC2+/
FISH+ or IHC3+) derived significant OS benefit from 
the addition of trastuzumab to chemotherapy (16 mo 
vs 11.8 mo, HR = 0.68). Moreover, the tolerability of 
the combination was good and there was no significant 
difference in the incidence of grade 3 or 4 side effects 
between the treatment groups. Based on these results, 
trastuzumab was approved in the Unites States and 
European Union for use in the first­line treatment of 
HER2­overexpressing locally advanced or metastatic 
GC. 
Pertuzumab is a new moAb that binds to the extra-
cellular ligand binding domain of HER2 and blocks its 
dimerization with other HER­family receptors[31]. When 
used together, the combination of pertuzumab plus 
trastuzumab provide a more comprehensive blockade 
of HER signalling than either agent alone. Therefore, the 
JACOB phase III study is currently recruiting participants 
to evaluate the effectiveness of pertuzumab in addition 
to trastuzumab plus chemotherapy (cisplatin plus 
capecitabine or 5­FU) in chemo­naïve patients with 
HER2­overexpressing advanced gastric or GEJ cancer 
(NCT01774786).
Trastuzumab emtansine (T­DM1) is a newly deve­
loped HER2­targeted antibody–drug conjugate that 
links trastuzumab to a highly potent maytansine­
derived anti­microtubule drug (DM1)[33]. After binding 
the trastuzumab moiety to HER2 receptors on the 
tumor surface, T­DM1 is internalized by endocytosis 
and degraded in lysosomes, resulting in release of DM1­
containing cytotoxic catabolites[33]. A phase II-III trial 
(NCT01641939) is now investigating the effectiveness 
of T­DM1 compared with taxanes (docetaxel or pacli­
taxel) in patients with metastatic HER2­positive GC 
who develop progression of disease following first­line 
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of the study also demonstrated geographical differences 
in the therapeutic effectiveness of bevacizumab 
treatment. A survival benefit for bevacizumab was 
demonstrated in patients recruited from North America 
and Latin America centers (median, 11.5 mo vs 6.8 mo 
for placebo­chemotherapy; HR = 0.63; 95%CI: 0.43 
to 0.94), whereas patients recruited from Asia centers 
seemed to have no obvious benefit (HR = 0.97; 95%CI: 
0.75 to 1.25). Subsequently, the study investigators 
identified plasma VEGF­A levels and degree of tumor 
neuropilin­1, a co­receptor for VEGF­A, expression 
as potential predictive biomarkers of bevacizumab 
efficacy[38]. A negative OS correlation was found in 
patients with low expression of tumor neuropilin­1 (HR = 
0.75; 95%CI: 0.59 to 0.97) compared to those with high 
expression (HR = 1.07; 95%CI: 0.81 to 1.40; interaction 
P = 0.06). Of note, these findings were significant only in 
non­Asian patients. 
AVATAR, a study similar in design to AVAGAST, was 
performed in Chinese patient population with advanced 
GC[39]. It was again demonstrated that the addition of 
bevacizumab to chemotherapy consisting capecitabine 
and cisplatin in this specific patient population did not 
improve OS (11.4 mo in the placebo arm vs 10.5 mo in 
the bevacizumab arm, HR = 1.11; P = 0.55). 
Ramucirumab is a novel humanized IgG1 moAb 
that selectively binds to the extracellular ligand binding 
domain of VEGFR­2 and blocks VEGF­induced angiogenic 
signaling[40]. In theory, this has the advantage of 
blocking signaling from VEGF isoforms other than 
VEGF­A. Its efficacy and safety in advanced GC was 
evaluated in two international, phase III, randomized, 
double­blinded and placebo­controlled studies. In the 
REGARD trial, a total 355 advanced gastric or GEJ 
cancer patients progressing after first­line platinum­ 
or fluoropyrimidine­based combination chemotherapy 
were randomized to receive best supportive care (BSC) 
plus either ramucirumab or placebo[41]. Ramucirumab 
was given intravenously every 2 wk at 8 mg/kg and the 
median treatment duration was 8 wk. Patients receiving 
ramucirumab had a significantly improved median OS 
(5.2 mo vs 3.8 mo; HR = 0.776; P = 0.0473) and PFS 
(2.1 mo vs 1.3 mo; HR = 0.483; P < 0.0001) than 
patients receiving placebo. The 12­wk PFS rate was 
40% for ramucirumab group and 16% for placebo 
group. Additionally, the overall response rate (3.4% vs 
2.6%) and disease control rate (49% vs 23%) were 
also higher in the ramucirumab group compared to 
the placebo group (P < 0.0001). Ramucirumab had 
an acceptable toxicity profile. The most frequently 
recorded grade 3 or higher side effects in patients 
receiving ramucirumab were hypertension, anemia, 
abdominal pain, ascites, fatigue and hyponatremia. 
After presentation of these results, ramucirumab was 
approved for the second­line therapy advanced GC in 
the United States. Interestingly, these results are quite 
similar to those achieved with chemotherapy in the 
second-line setting[42].
The RAINBOW study tested ramucirumab in combi­
nation with paclitaxel in metastatic GEJ or gastric 
adenocarcinoma patients who experienced disease 
progression after first­line platinum­ and fluoropyri­
midine­based chemotherapy[43]. In this study, 665 
patients were randomly assigned to receive ramuciru­
mab or placebo plus paclitaxel. OS was defined again 
primary endpoint for efficacy. Median OS for patients 
received ramucirumab plus paclitaxel was 9.6 mo, 
compared to 7.4 mo for those received paclitaxel alone 
(HR = 0.807; 95%CI: 0.678­0.962; P = 0.0169). 
Median PFS was 4.4 mo and 2.9 mo, respectively (HR = 
0.635; 95%CI: 0.536­0.752; P < 0.0001). The objective 
response rate was higher in the combination arm 
compared to paclitaxel alone arm (28% vs 16%, P = 
0.0001). Ramucirumab was relatively well tolerated. As 
expected, grade 3 or higher side effects were somewhat 
more frequent among patients receiving ramucirumab 
plus paclitaxel greater with combination treatment and 
included neutropenia, leukopenia, hypertension and 
fatigue. The RAINBOW study showed that an effective 
second­line treatment may improve the duration of 
survival in metastatic GC, and it is the only study to 
date to demonstrate a 2­mo improvement in OS in 
this setting. Therefore, ramucirumab is the first anti-
angiogenic agent to demonstrate activity for advanced 
GC, and now approved both as monotherapy and in 
combination with paclitaxel for this malignancy. 
Anti-VEGF TKI: Apatinib is an orally administered TKI 
that selectively binds to VEGFR­2 and inhibits VEGF­
induced endothelial cell proliferation and migration. 
As a result, it leads to a significant decrease in tumor 
microvessel density[44]. In a phase II trial conducted in 
China, apatinib was shown to increase PFS and OS in 
patients with metastatic GC progressing after 2 or more 
previous lines of chemotherapy[45]. Data from a phase 
III trial presented at the 2014 ASCO Annual Meeting 
confirmed the effectiveness of apatinib in this setting[46]. 
This trial included 273 patients with advanced GC who 
experienced disease progression after second­line 
treatment. Patients were randomly assigned to receive 
apatinib or placebo. The primary endpoint, median OS, 
was significantly longer in the apatinib group than in the 
placebo group (195 d vs 140 d; HR = 0.71; 95%CI: 
0.54­0.94; P < 0.016). The apatinib group also had a 
better median PFS than the placebo group; 78 d vs 
53 d, respectively (HR = 0.44; 95%CI: 0.33­0.61; P < 
0.0001). Therefore, apatinib provides a new promising 
treatment option for advanced GC, although one which 
overlaps with ramucirumab in both degree of activity 
and mechanism. 
Two multi­targeted kinase inhibitors that share VEGF 
receptors as targets are sunitinib and sorafenib. Both of 
these agents have been tested in GC and have shown 
some signs of efficacy, but have not progressed to 
advanced trials[47­49]. Given the modest activity and the 
toxicity profiles of these two agents, it is unlikely that 
they would supplant ramucirumab at this time and are 
no longer being studied in GC. 
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The mTOR pathway: The mTOR (mammalian target 
of rapamycin) is an essential cellular signaling pathway 
that has a crucial role in the regulation of cell growth, 
survival, proliferation, metabolism, and angiogenesis[50]. 
Everolimus, an orally administered rapamycin analog, 
is the only mTOR inhibitor that has been evaluated 
in advanced GC[51]. Phase II trials documented that it 
can produce stabile disease in a significant portion of 
patients with chemo­refractory advanced GC. Despite 
these promising data, in the phase III GRANITE­1 
trial, everolimus failed to demonstrate any significant 
improvement in OS compared to BSC alone[52]. In 
this study, advanced GC patients who had progressive 
disease after first- or second-line cytotoxic chemo-
therapy were randomized to receive everolimus treat­
ment (10 mg/d) or matching placebo in conjunction 
with BSC. Median OS was 5.4 mo for patients receiving 
everolimus and 4.3 mo for patients receiving placebo 
(HR = 0.90; 95%CI: 0.75 to 1.08; P = 0.124). Another 
phase III trial (AIO­STO­0111) is now investigating the 
efficacy of everolimus when given in combination with 
paclitaxel in GC patients progressing following prior 
chemotherapy regimen. 
Targeting the hepatocyte growth factor/c-MET signaling 
pathway
A transmembrane protein­tyrosine kinase receptor c­MET 
and its ligand, hepatocyte growth factor (HGF) control 
many vital cellular events such as cell proliferation, 
survival, motility, invasion and angiogenesis[53]. C-MET 
overexpression has been detected in 18%­82% of 
GC patients, with genetic amplification of the CMET 
occurring in only 2%-3% of cases[54]. Patients with c-Met 
overexpressing tumors may have poorer survival, and 
the prognostic effect of overexpression seems to be 
independent of disease stage[53]. Therefore, c-MET has 
been recognized as potentially significant therapeutic 
target in GC. 
Rilotumumab is a fully humanized IgG2 moAb 
that selectively binds HGF and prevents its binding to 
the MET receptor[53]. The results of a phase Ib/II study 
of rilotumumab in combination with platinum­based 
chemotherapy in patients with locally advanced or 
metastatic GC have demonstrated the potential thera­
peutic value of drugs that target the c­MET pathway in 
this disease[55]. In the phase II part of this study, 121 
patients were randomized to ECX regimen plus placebo 
(n = 39) or ECX plus either 7.5 mg/kg (n = 42) or 15 
mg/kg (n = 40) rilotumumab. Median PFS was 5.1 mo 
(2.9­7.0) in the rilotumumab 15 mg/kg group, 6.8 mo 
(4.5­7.5) in the rilotumumab 7.5 mg/kg group, 5.7 mo 
(4.5­7.0) in both rilotumumab groups combined, and 
4.2 mo (2.9­4.9) in the placebo group. The HR for PFS 
compared with placebo was 0.69 (80%CI: 0.49­0.97; 
P = 0.164) for rilotumumab 15 mg/kg, 0.53 (80%CI: 
0.38­0.73; P = 0.009) for rilotumumab 7.5 mg/kg, 
and 0.60 (80%CI: 0.45­0.79; P = 0.016) for combined 
rilotumumab. Rilotumumab was generally well tolerated 
by patients, with common side effects including neutro­
penia, anemia, thrombocytopenia, peripheral edema, 
and deep vein thrombosis. The association between MET 
expression and clinical outcomes was also evaluated in 
this trial. MET expression was found to be prognostic 
for shortened OS in the placebo group (5.7 mo vs 11.5 
mo). In the subgroup of patients with increased MET 
expression, median OS was longer in patients receiving 
rilotumumab than in those receiving placebo (10.6 mo 
vs 5.7 mo). However, no survival benefit was seen with 
the addition of rilotumumab to chemotherapy among 
MET­negative patients. 
Based on these data, the RILOMET­1 [a multicenter, 
randomized, double­blind, placebo­controlled phase III 
study of rilotumumab (15 mg/kg) plus ECX regimen 
as first­line therapy for metastatic MET­positive gastric 
or GEJ adenocarcinoma] and the RILOMET­2 trial 
(a multicenter, randomized, double­blind, placebo 
controlled phase III  study of rilotumumab plus cisplatin 
and capecitabine regimen as first­line therapy for 
Asian patients with metastatic MET­positive gastric 
or GEJ cancer) have been conducted. Unfortunately, 
the RILOMET­1 study has been reported as negative 
via press release (AMGEN press release), with final 
presentation of data pending at an upcoming meeting. 
Onartuzumab is an Escherichia coli­derived humanized 
monovalent moAb against MET that specifically binds to 
the MET receptor and blocks HGF­MET binding[56]. Shah 
et al[57] have presented the results of a phase II trial that 
compared FOLFOX plus onartuzumab vs FOLFOX plus 
placebo in patients with metastatic gastroesophageal 
adenocarcinoma. The primary endpoint of the trial was 
not met (6.77 mo in onartuzumab arm vs 6.97 mo in the 
placebo arm, HR = 1.08; 95%CI: 0.71­1.63). In MET­
positive patients, PFS was 5.95 mo for patients receiving 
onartuzumab vs 6.8 mo for those in the placebo arm (HR 
= 1.38; 95%CI: 0.60­3.20). Serious adverse events, 
including neutropenia, thrombocytopenia, peripheral 
edema, and pulmonary embolism also occurred more 
frequently in patients on onartuzumab (55% vs 40%). 
The phase III MetGastric trial will assess the 
effectiveness and toxicity of onartuzumab in combination 
with modified­FOLFOX6 chemotherapy in patients with 
metastatic HER2­negative and MET­positive gastric or 
GEJ adenocarcinoma[58]. In this study, enrolled patients 
will receive the chemotherapy with either onartuzumab 
or placebo, and patients who have not progressed 
after 12 cycles of treatment will continue with either 
onartuzumab or placebo until evidence of disease 
progression or intolerable toxicity. 
Targeting programmed cell death-1 receptor and its 
ligand 
Programmed cell death-1 (PD­1) is a cell surface and 
immune inhibitory receptor expressed on a variety 
of immune cells, especially cytotoxic T cells. Two 
distinct ligands for PD­1 were identified: Programmed 
death ligand 1 (PD­L1) and PD­L2[59]. While PD­L2 is 
expressed mainly on macrophages and dendritic cells, 
PDL­1 is expressed exclusively by tumor cells and their 
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microenvironment[60]. Tumors that express PD­L1 often 
tend to be aggressive and carry a poor prognosis[61]. 
Tumor cells utilize the PD­1/PD­L1 pathway to evade 
immune­cell attack. Activation of this pathway in tumor 
cells blocks T-cell-mediated cytotoxicity and allows tumor 
cells to continue to proliferate[59­61]. Drugs targeting 
PD­L1 pathway may stimulate antitumor immunity, 
especially (although not exclusively) in PD­L1 positive 
tumors. 
At the 2014 European Society for Medical Oncology 
meeting, data on safety and tolerability, and preliminary 
anti­tumor efficacy of pembrolizumab in advanced GC 
patients were presented by Muro et al[62] (KEYNOTE­012 
study). This drug is a selective and humanized moAb 
that blocks interaction between PD­1 and its ligands 
PD­L1 and PD­L2. Muro et al[62] enrolled 39 patients 
with PD­L1 positive advanced GC: 19 from Asia­Pacific, 
20 from rest of world. Sixty­seven percent of these 
patients had received more than 2 chemotherapy lines. 
Pembrolizumab was administered 10 mg/kg once every 
2 wk for up to 24 mo in the absence of intolerable 
toxicity or disease progression. The overall response 
rate was 31.6% in patients in the Asia­Pacific region and 
30% in patients from rest the world. Median duration 
of response has not yet been reached at the time of 
initial presentation, but ranged from 8+ to 20+ wk. 
Four patients developed grade 3­5 drug­related adverse 
events including peripheral sensory neuropathy, fatigue, 
decreased appetite, hypoxia, and pneumonitis (n = 1 
each). One treatment­related death was recorded due to 
hypoxia. The authors of the study have concluded that 
pembrolizumab treatment seems to have and acceptable 
safety and tolerability profile and it provides encouraging 
clinical antitumor activity in chemo-refractory disease. 
On the basis of these promising preliminary data, phase 
II KEYNOTE­059 study will be initiated to evaluate 
pembrolizumab as single agent or in combination with 
cisplatin and 5­FU in patients with metastatic PD­L1 
positive gastric or GEJ adenocarcinoma. 
Recent analysis from the Gastric Cancer Genome 
Atlas Project: The Cancer Genome Atlas is a large-
scale effort coordinated by the United States National 
Cancer Institute to extensively characterize the genetic 
and epigenetic landscape of human cancers. The 
group has reported on the analysis of 259 untreated 
primary gastric cancers. This analysis proposed dividing 
gastric cancer into 4 molecular subtypes: EBV driven, 
microsatellite unstable (MSI high), genomic stable 
and chromosomal unstable tumors. This molecular 
subtyping highlights important targets within these 
groups for further study, and potentially allows for 
patient enrichment that could result in higher chance of 
positive trial results. For example, EBV driven tumors 
are characterized by high rate of PIK3CA mutations, 
where drugs targeting the Pi3K pathway are available in 
clinical trials[63]. Additionally, EBV­positive gastric cancers 
preferentially overexpress CD274 and PDCD1LG2 (PD­L1 
and PD­L2) that were discussed above[64]. These are 
currently being evaluated as predictive biomarkers for 
immune checkpoint inhibitor activity[65,66]. In addition, 
this subgroup has significant promoter hypermethylation, 
such that evaluating hypomethylating agents such as 
azacitidine, decitabine and others in clinical development 
might represent a promising strategy. 
The MSI­high genotype is associated with high 
mutational rate, representing a wealth of antigens 
that could be recognized by the immune system[67,68]. 
This genotype has been proposed to be responsive 
to checkpoint inhibitors, and clinical trials are ongoing 
(NCT01876511, NCT02060188) addressing response 
to checkpoint inhibitors in MSI high gastrointestinal 
cancers. 
Other mutations that have been reported (KRAS, 
P53, APC, and CTNNB1) are still challenging to target 
and are the subject of numerous reviews. Knowledge of 
frequency of mutation of these genes, however, provides 
impetus for further basic research. For example, cell 
cycle regulators could have better chance of activity in 
P53 mutant tumors[69,70]. Lastly, the WNT/beta catenin 
pathway is currently a focus of much preclinical and 
clinical research[71]. 
CONCLUSION
Gastric cancer has long represented one of the most 
difficult gastrointestinal malignancies to treat. Encour­
agingly, recent progress with targeted therapies offers 
hope for patients with advanced GC, and expands the 
therapeutic armamentarium considerably against this 
formidable disease. As these therapies continue to be 
developed, we must focus on determination of predictive 
markers, and preferably co­develop drugs with these 
markers. The mechanisms underlying primary or 
acquired resistance to targeted agents also should be 
clarified in order to help further drug development. 
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Figure 2  Proposed targeted therapy algorithm for advanced gastric 
cancer. CF: Cisplatin plus 5-Fluorouracil; HER: Human epidermal growth factor 
receptor; CX: Cisplatin plus capecitabine.
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We propose a treatment algorithm that is consistent 
with current National Cancer Center Network guidelines 
(version 3, 2015) and that integrates targeted therapies 
into the management of advanced GC (Figure 2). The 
addition of trastuzumab to a first­line chemotherapy 
doublet (cisplatin and capecitabine or 5­FU) is now 
considered standard of care for patients with HER2 
positive advanced GC. The results of the phase III 
JACOB trial are awaited with great interest to see if the 
combined use of trastuzumab and pertuzumab can 
improve clinical outcome. Anti­angiogenic therapy has 
failed to meet the expectations as first­line treatment. 
But second­line treatment with ramucirumab or apa­
tinib now represents a good alternative for chemo­
refractory GC patients for whom the options are still are 
quite limited. Other targeted agents currently under 
evaluation in clinical trials including inhibitors of m­TOR, 
c­MET, IGFR, and FGFR pathways can help expand our 
treatment repertoire in the future against advanced 
GC. Lastly, knowledge gained from detailed molecular 
profiling of gastric cancers gives us a roadmap for future 
basic and clinical research.
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